Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 9/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 9/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 9/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 9/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 0.57 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7369768 | 0.86 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPTPN11 | |
| SCHEMBL8683735 | 0.84 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4DLPAR1 | |
| SCHEMBL4062544 | 0.84 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4DLPAR1 | |
| SCHEMBL7153812 | 0.83 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7376634 | 0.83 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9148374 | 0.82 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DF2 | |
| SCHEMBL6584958 | 0.79 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8686439 | 0.78 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DRARB | |
| SCHEMBL6942928 | 0.78 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3095526 | 0.77 | PDE4A (0.62) | PDE4APDE4BPDE4CPDE4DRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803760-B2 | Methods of inducing ovulation | MERCK SERONO SA (CH) | 2010-09-28 | — | — | US | claimed |
| JP-4532115-B2 | — | — | 2010-08-25 | — | — | JP | claimed |
| US-20080293622-A1 | METHODS OF INDUCING OVULATION | MERCK SERONO SA (CH) | 2008-11-27 | — | — | US | claimed |
| US-6953774-B2 | Methods of inducing ovulation | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-10-11 | — | — | US | claimed |
| US-20050148501-A1 | Methods of inducing ovulation using a non-polypeptide camp level modulator | MERCK SERONO SA (CH) | 2005-07-07 | — | — | US | claimed |
| EP-1463493-A1 | METHODS OF INDUCING OVULATION-USING A NON-POLYPEPTIDE CAMP LEVEL MODULATOR | Applied Research Systems ARS Holding N.V. (AN) | 2004-10-06 | — | — | EP | claimed |
| WO-2003051344-A1 | METHODS OF INDUCING OVULATION_USING A NON-POLYPEPTIDE CAMP LEVEL MODULATOR | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-06-26 | — | — | WO | claimed |
| US-20020103106-A1 | Methods of inducing ovulation | MERCK SERONO SA (CH) | 2002-08-01 | — | — | US | claimed |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | disclosed |
| EP-2804603-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2014-11-26 | — | — | EP | disclosed |
| WO-2013106547-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-18 | — | — | WO | disclosed |
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011146819-A2 | METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES | DMD THERAPIES, LLC (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2004067006-A1 | COMBINATION OF A PDE IV INHIBITOR AND A TNF-ALPHA ANTAGONIST | PHARMACIA CORPORATION (US) | 2004-08-12 | — | — | WO | disclosed |
| WO-2003051344-A1 | METHODS OF INDUCING OVULATION_USING A NON-POLYPEPTIDE CAMP LEVEL MODULATOR | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-06-26 | — | — | WO | disclosed |
| US-20020103106-A1 | Methods of inducing ovulation | MERCK SERONO SA (CH) | 2002-08-01 | — | — | US | disclosed |
| US-5814651-A | PHOSPHODIESTERASE TYPE FOUR INHIBITORS | PFIZER INC. (US) | 1998-09-29 | — | — | US | disclosed |
| EP-0672031-A1 | CATECHOL DIETHERS AS SELECTIVE PDE IV? INHIBITORS | PFIZER INC. (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994012461-A1 | CATECHOL DIETHERS AS SELECTIVE PDEIV INHIBITORS | PFIZER INC. (US) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | PDE4A 167/4885PDE4B 186/4885PDE4C 171/4885 |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | IAPP, GPR119, PCNA | PDE4A 1173/4885PDE4B 1204/4885PDE4C 1042/4885 |
| US-20050148501-A1 | Methods of inducing ovulation using a non-polypeptide camp level modulator | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
| US-20020103106-A1 | Methods of inducing ovulation | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
| US-20080293622-A1 | METHODS OF INDUCING OVULATION | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.